Icatibant Dosing & Reconstitution Guide

Route: Subcutaneous injection

Frequency: As needed for acute HAE attacks

Dose Range: 30 mg

Safety data from pivotal clinical trials indicate that injection site reactions are the most frequently observed adverse events, occurring in approximately 97% of patients, typically manifesting as erythema, swelling, burning, or pruritus at the site of injection. These reactions are generally mild and self-limiting, resolving within hours. Other common adverse events, occurring in 1-10% of cases, include pyrexia, transient elevations in liver enzymes, dizziness, headache, nausea, and rash. Notably, no serious drug-related adverse events have been reported in these trials. Contraindications include known hypersensitivity to Icatibant or its components, as well as its use in patients experiencing laryngeal attacks without additional emergency interventions, given the life-threatening nature of such incidents. Furthermore, the use of Icatibant is not recommended in individuals with acute ischemic heart disease or unstable angina due to the potential attenuation of the protective effects of bradykinin.